Showing results (161-170 of 227) with videos related to

Sort By:
Pageof 23
The Journal of Urology|June 1, 1991
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup StudyD G McLeod, R B Weiss, D M Stablein, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Biochemical Pharmacology|October 5, 1993
Effects of temperature on the interaction of cisplatin and carboplatin with cellular DNAG Los, M J van Vugt, L den Engelse, et al.
Head & Neck|October 10, 2001
Nicotine affects the signaling of the death pathway, reducing the response of head and neck cancer cell lines to DNA damaging agentsN Onoda, A Nehmi, D Weiner, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Intraperitoneal 5-fluoro-2'-deoxyuridine (FUDR) and (S)-leucovorin for disease predominantly confined to the peritoneal cavity: a pharmacokinetic and toxicity studyV K Israel, C Jiang, F M Muggia, et al.
Cancer Treatment Reports|January 1, 1979
VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474)D F Chiuten, J M Bennett, R H Creech, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adductsI Gill, F M Muggia, P M Terheggen, et al.
British Journal of Cancer|November 17, 2001
Identification of gene clusters differentially expressed during the cellular injury responses (CIR) to cisplatinA Johnsson, P Byrne, R de Bruin, et al.
Cancer Research|March 1, 1986
In vivo 31P-nuclear magnetic resonance study of the response of a murine mammary tumor to different doses of gamma-radiationP E Sijens, W M Bovée, D Seijkens, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell linesB Nakata, K D Albright, R M Barton, et al.
Pageof 23